By Cecilia Butini

GlaxoSmithKline PLC said Thursday that it has kicked off a trial as part of its Phase 3 clinical program to test a treatment for severe eosinophilic asthma.

The trial, named SWIFT-2, is for an investigational medicine called GSK'294, a monoclonal antibody which is meant to suppress the protein responsible for the spread of eosinophils, a type of white blood cell involved in severe asthma.

The medicine is delivered as a subcutaneous injection every six months, GSK said.

Write to Cecilia Butini at cecilia.butini@wsj.com

(END) Dow Jones Newswires

March 18, 2021 06:08 ET (10:08 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.
Gsk (LSE:GSK)
過去 株価チャート
から 3 2024 まで 4 2024 Gskのチャートをもっと見るにはこちらをクリック
Gsk (LSE:GSK)
過去 株価チャート
から 4 2023 まで 4 2024 Gskのチャートをもっと見るにはこちらをクリック